Search

Your search keyword '"Patruno, Cataldo"' showing total 963 results
Start Over Author "Patruno, Cataldo"
963 results on '"Patruno, Cataldo"'

4. AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History

Author

Stingeni, Luca, Chiricozzi, Andrea, Calzavara-Pinton, Piergiacomo, Napolitano, Maddalena, Peris, Ketty, Schena, Donatella, Patruno, Cataldo, Rossi, Mariateresa, Foti, Caterina, Fargnoli, Maria C., Corazza, Monica, Ferrucci, Silvia M., Pigatto, Paolo D., Romanelli, Marco, Fabbrocini, Gabriella, Girolomoni, Giampiero, Passante, Maria, Romita, Paolo, Esposito, Maria, Schettini, Natale, Marzano, Angelo V., Tonini, Giulia, Marietti, Rossella, Casciola, Gabriele, Argenziano, Giuseppe, and Hansel, Katharina

Published
2024
Full Text
View/download PDF

5. Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials

Author

Silverberg, Jonathan I, Lynde, Charles W, Abuabara, Katrina, Patruno, Cataldo, de Benedetto, Anna, Zhang, Haixin, Thomas, Ryan B, Bégo-Le-Bagousse, Gaëlle, Khokhar, Faisal A, Vakil, Jignesh, Marco, Ainara Rodríguez, and Levit, Noah A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Trials and Supportive Activities, Clinical Research, Aging, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Skin, Humans, Adult, Middle Aged, Aged, Dermatitis, Atopic, Quality of Life, Injections, Subcutaneous, Double-Blind Method, Severity of Illness Index, Randomized Controlled Trials as Topic, Treatment Outcome, Dermatology & Venereal Diseases, Clinical sciences
Abstract

BackgroundAdults aged ≥ 60 years are often underrepresented in atopic dermatitis (AD) clinical trials; age-related comorbidities may impact treatment efficacy and safety.ObjectiveThe aim was to report dupilumab efficacy and safety in patients aged ≥ 60 years with moderate-to-severe AD.MethodsData were pooled from four randomized, placebo-controlled dupilumab trials of patients with moderate-to-severe AD (LIBERTY AD SOLO 1 and 2, LIBERTY AD CAFÉ, and LIBERTY AD CHRONOS) and stratified by age (

Published
2023

6. Correction to: AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History

Author

Stingeni, Luca, Chiricozzi, Andrea, Calzavara-Pinton, Piergiacomo, Napolitano, Maddalena, Peris, Ketty, Schena, Donatella, Patruno, Cataldo, Rossi, Mariateresa, Foti, Caterina, Fargnoli, Maria C., Corazza, Monica, Ferrucci, Silvia M., Pigatto, Paolo D., Romanelli, Marco, Fabbrocini, Gabriella, Girolomoni, Giampiero, Passante, Maria, Romita, Paolo, Esposito, Maria, Schettini, Natale, Marzano, Angelo V., Tonini, Giulia, Marietti, Rossella, Casciola, Gabriele, Argenziano, Giuseppe, and Hansel, Katharina

Published
2024
Full Text
View/download PDF

8. Dupilumab Treatment in Children Aged 6–11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study

Author

Napolitano, Maddalena, Fabbrocini, Gabriella, Neri, Iria, Stingeni, Luca, Boccaletti, Valeria, Piccolo, Vincenzo, Amoruso, Giuseppe Fabrizio, Malara, Giovanna, De Pasquale, Rocco, Di Brizzi, Eugenia Veronica, Diluvio, Laura, Bianchi, Luca, Chiricozzi, Andrea, Di Guida, Adriana, Del Duca, Elisabetta, Moschese, Viviana, Di Lernia, Vito, Dragoni, Federica, Gruber, Michaela, Hansel, Katharina, Licari, Amelia, Manti, Sara, Leonardi, Salvatore, Mastorino, Luca, Ortoncelli, Michela, Provenzano, Eugenio, Palermo, Antonino, Patella, Vincenzo, Peduto, Tiziana, Pezzolo, Elena, Piras, Viviana, Potestio, Luca, Battista, Teresa, Satta, Rosanna, Termine, Stefania, Palma, Paolo, Zangari, Paola, and Patruno, Cataldo

Published
2022
Full Text
View/download PDF

9. Short-, mid- and long-term efficacy of dupilumab in moderate to severe atopic dermatitis: a real life multicenter Italian study on 2576 patients

Author

Ferrucci, Silvia, primary, Tavecchio, Simona, additional, Maronese, Carlo Alberto, additional, Balato, Anna, additional, Di Brizzi, Eugenia, additional, Ortoncelli, Michela, additional, Ribero, Simone, additional, Girolomoni, Giampiero, additional, Maurelli, Martina, additional, Belloni Fortina, Anna, additional, Caroppo, Francesca, additional, Naldi, Luigi, additional, Pezzolo, Elena, additional, Nettis, Eustachio, additional, Pugliese, Francesco, additional, Stingeni, Luca, additional, Hansel, Katharina, additional, Rubegni, Giovanni, additional, Calabrese, Laura, additional, Russo, Filomena, additional, Gola, Massimo, additional, Magnaterra, Elisabetta, additional, Rongioletti, Franco, additional, Mercuri, Santo Raffaele, additional, Paolino, Giovanni, additional, Savoia, Paola, additional, Veronese, Federica, additional, Foti, Caterina, additional, Ambrogio, Francesca, additional, Scalvenzi, Massimiliano, additional, Napolitano, Maddalena, additional, Patruno, Cataldo, additional, Dastoli, Stefano, additional, Corazza, Monica, additional, Borghi, Alessandro, additional, Calzavara-Pinton, Pier Giacomo, additional, Rossi, Mariateresa, additional, Offidani, Annamaria, additional, Radi, Giulia, additional, Bonzano, Laura, additional, Ferreli, Caterina, additional, Piras, Viviana, additional, Satta, Rosanna, additional, Sucato, Federica, additional, Malagoli, Piergiorgio, additional, Gaiani, Francesca, additional, Micali, Giuseppe, additional, Musumeci, Maria Letizia, additional, Fargnoli, Maria Concetta, additional, Esposito, Maria, additional, Grieco, Teresa, additional, Chello, Camilla, additional, Casazza, Giovanni, additional, and Marzano, Angelo, additional

Published
2024
Full Text
View/download PDF

10. Italian S3-Guideline on the treatment of Atopic Eczema - Part 1: Systemic therapy, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Environmental Dermatology (SIDAPA)

Author

ARGENZIANO, Giuseppe, primary, CUSANO, Francesco, additional, CORAZZA, Monica, additional, AMATO, Salvatore, additional, AMERIO, Paolo, additional, NALDI, Luigi, additional, PATRUNO, Cataldo, additional, PIGATTO, Paolo D., additional, QUAGLINO, Pietro, additional, GISONDI, Paolo, additional, CHIRICOZZI, Andrea, additional, TONON, Francesco, additional, STINGENI, Luca, additional, CALZAVARA-PINTON, Piergiacomo, additional, WOLLENBERG, Andreas, additional, KINBERGER, Maria, additional, ARENTS, Bernd W., additional, ASZODI, Nora, additional, AVILA VALLE, Gabriela L., additional, BARBAROT, Sebastien, additional, BIEBER, Thomas, additional, BROUGH, Helen A., additional, CHRISTEN-ZÄCH, Stéphanie, additional, DELEURAN, Mette, additional, DITTMANN, Martin, additional, DRESSLER, Corinna, additional, FINK-WAGNER, Antjie H., additional, FOSSE, Nicole, additional, GÁSPÁR, Krisztián, additional, GERBENS, Louise A., additional, GIELER, Uwe, additional, GIROLOMONI, Giampiero, additional, GREGORIOU, Stamatios, additional, MORTZ, Charlotte G., additional, NAST, Alexander, additional, NYGAARD, Uffe, additional, REDDING, Magali, additional, REHBINDER, Eva M., additional, RING, Johannes, additional, ROSSI, Mariateresa, additional, SERRA-BALDRICH, Esther, additional, SIMON, Dagmar, additional, SZALAI, Zsuzsanna Z., additional, SZEPIETOWSKI, Jacek C., additional, TORRELO, Antonio, additional, WERFEL, Thomas, additional, and FLOHR, Carsten, additional

Published
2024
Full Text
View/download PDF

11. Clinical outcomes and management of JAK inhibitor-associated acne in patients with moderate-to-severe atopic dermatitis undergoing upadacitinib: A multicenter retrospective study

Author

Avallone, Gianluca, primary, Mastorino, Luca, additional, Tavoletti, Gianluca, additional, Macagno, Nicole, additional, Barei, Francesca, additional, Schena, Donatella, additional, Rossi, Mariateresa, additional, Magnaterra, Elisabetta, additional, Antonelli, Flaminia, additional, Babino, Graziella, additional, Viola, Riccardo, additional, Gargiulo, Luigi, additional, Conforti, Claudio, additional, Rapparini, Luca, additional, Errichetti, Enzo, additional, Patruno, Cataldo, additional, Ruggiero, Pasqualina, additional, Roccuzzo, Gabriele, additional, Maronese, Carlo A., additional, Girolomoni, Giampiero, additional, Gola, Massimo, additional, Chiricozzi, Andrea, additional, Balato, Anna, additional, Ambrogio, Francesca, additional, Narcisi, Alessandra, additional, Zalaudek, Iris, additional, Gurioli, Carlotta, additional, Napolitano, Maddalena, additional, Marzano, Angelo V., additional, Foti, Caterina, additional, Costanzo, Antonio, additional, Piraccini, Bianca M., additional, Ferrucci, Silvia M., additional, Ortoncelli, Michela, additional, Quaglino, Pietro, additional, and Ribero, Simone, additional

Published
2024
Full Text
View/download PDF

12. Italian S3-Guideline on the treatment of atopic eczema - First Update, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA)

Author

ARGENZIANO, Giuseppe, primary, CUSANO, Francesco, additional, CORAZZA, Monica, additional, AMATO, Salvatore, additional, AMERIO, Paolo, additional, NALDI, Luigi, additional, PATRUNO, Cataldo, additional, PIGATTO, Paolo D., additional, QUAGLINO, Pietro, additional, GISONDI, Paolo, additional, CHIRICOZZI, Andrea, additional, TONON, Francesco, additional, STINGENI, Luca, additional, CALZAVARA-PINTON, Piergiacomo, additional, WOLLENBERG, Andreas, additional, KINBERGER, Maria, additional, ARENTS, Bernd W., additional, ASZODI, Nora, additional, AVILA VALLE, Gabriela L., additional, BARBAROT, Sebastien, additional, BIEBER, Thomas, additional, BROUGH, Helen A., additional, CHRISTEN-ZÄCH, Stéphanie, additional, DELEURAN, Mette, additional, DITTMANN, Martin, additional, DRESSLER, Corinna, additional, FINK-WAGNER, Antjie H., additional, FOSSE, Nicole, additional, GÁSPÁR, Krisztián, additional, GERBENS, Louise A., additional, GIELER, Uwe, additional, GIROLOMONI, Giampiero, additional, GREGORIOU, Stamatios, additional, MORTZ, Charlotte G., additional, NAST, Alexander, additional, NYGAARD, Uffe, additional, REDDING, Magali, additional, REHBINDER, Eva M., additional, RING, Johannes, additional, ROSSI, Mariateresa, additional, SERRA-BALDRICH, Esther, additional, SIMON, Dagmar, additional, SZALAI, Zsuzsanna Z., additional, SZEPIETOWSKI, Jacek C., additional, TORRELO, Antonio, additional, WERFEL, Thomas, additional, and FLOHR, Carsten, additional

Published
2024
Full Text
View/download PDF

13. Italian S3-Guideline on the treatment of atopic eczema Part 2: non-systemic treatments and treatment recommendations for special AE patient populations, adapted from EuroGuiDerm by the Italian Society of Dermatology and STD (SIDEMAST), the Italian Association of Hospital Dermatologists (ADOI) and the Italian Society of Allergological and Occupational Dermatology (SIDAPA)

Author

ARGENZIANO, Giuseppe, primary, CUSANO, Francesco, additional, CORAZZA, Monica, additional, AMATO, Salvatore, additional, AMERIO, Paolo, additional, NALDI, Luigi, additional, PATRUNO, Cataldo, additional, PIGATTO, Paolo D., additional, QUAGLINO, Pietro, additional, GISONDI, Paolo, additional, CHIRICOZZI, Andrea, additional, TONON, Francesco, additional, STINGENI, Luca, additional, CALZAVARA-PINTON, Piergiacomo, additional, WOLLENBERG, Andreas, additional, KINBERGER, Maria, additional, ARENTS, Bernd W., additional, ASZODI, Nora, additional, AVILA VALLE, Gabriela L., additional, BARBAROT, Sebastien, additional, BIEBER, Thomas, additional, BROUGH, Helen A., additional, CHRISTEN-ZÄCH, Stéphanie, additional, DELEURAN, Mette, additional, DITTMANN, Martin, additional, DRESSLER, Corinna, additional, FINK-WAGNER, Antjie H., additional, FOSSE, Nicole, additional, GÁSPÁR, Krisztián, additional, GERBENS, Louise A., additional, GIELER, Uwe, additional, GIROLOMONI, Giampiero, additional, GREGORIOU, Stamatios, additional, MORTZ, Charlotte G., additional, NAST, Alexander, additional, NYGAARD, Uffe, additional, REDDING, Magali, additional, REHBINDER, Eva M., additional, RING, Johannes, additional, ROSSI, Mariateresa, additional, SERRA-BALDRICH, Esther, additional, SIMON, Dagmar, additional, SZALAI, Zsuzsanna Z., additional, SZEPIETOWSKI, Jacek C., additional, TORRELO, Antonio, additional, WERFEL, Thomas, additional, and FLOHR, Carsten, additional

Published
2024
Full Text
View/download PDF

17. The new Italian SIDAPA Baseline Series for patch testing (2023): an update according to the new regulatory pathway for contact allergens

Author

Luca, S, Leonardo, B, S, C, Fortina Anna, B, Francesca, C, Monica, C, Alessandro, B, Rosella, G, Ilaria, T, M, F, Andrea, B, Fabrizio, G, Emanuela, M, Maddalena, N, Lucia Mario, D, Cataldo, P, Luigi, B, Paolo, R, Caterina, F, Marta, T, Rossella, M, Giuseppe, A, Katharina, H, Abategiovanni, L, Albertazzi, D, Ali Biglu Marash, S, Amendolagine, G, Angelini, G, Annunziata, A, Assalve, D, Ayala, F, Babino, G, Barruscotti, S, Battista, T, Berta, M, Biondi, F, Boccaletti, V, Bonamonte, D, Bruni, F, Buffon, R, Caccavale, S, Calabrese, L, Calzavara Pinton, P, Camela, E, Carugno, A, Casciola, G, Cecchini, E, Cristaudo, A, D'Agostino, M, Damiani, G, Danese, P, Dattola, A, DE Salvo, V, Errichetti, E, Esposito, G, Esposito, M, Fantini, C, Fontana, E, Fornaro, L, Adina Frasin, L, Galeotti, T, Gasparini, G, Genco, L, Gravante, M, Guastaferro, D, Guerrasio, G, Guerriero, L, Lauro, W, Lucagnano, G, Malatesta, N, Desmond Mandel, V, Marano, L, Marino, V, Martora, F, Menna, L, Miano, C, Miccio, L, Michelerio, A, Milanesi, N, Monfrecola, G, Motolese, A, Nocerino, M, Noto, M, Ornielli, M, Pacifico, A, Papini, M, Pasolini, G, Penchini, L, Perazzolli, G, Peserico, A, Piccolo, V, Pigatto, P, Potestio, L, Pugliese, A, Recalcati, S, Rivetti, N, Rossi, M, Russo, F, Russo, T, Schena, D, Sensini, C, Tesauri, D, Marco Tomassini, G, Ventura, V, Venturini, M, Vezzoli, P, Vincenzi, C, Stingeni Luca, Bianchi Leonardo, Caroppo Elena S, Belloni Fortina Anna, Caroppo Francesca, Corazza Monica, Borghi Alessandro, Gallo Rosella, Trave Ilaria, Ferrucci Silvia M, Beretta Andrea, Guarneri Fabrizio, Martina Emanuela, Napolitano Maddalena, De Lucia Mario, Patruno Cataldo, Bennardo Luigi, Romita Paolo, Foti Caterina, Tramontana Marta, Marietti Rossella, Argenziano Giuseppe, Hansel Katharina, Luisa Abategiovanni, Donatella Albertazzi, Samane Ali Biglu Marash, Graziana Amendolagine, Gianni Angelini, Alberto Annunziata, Danilo Assalve, Fabio Ayala, Graziella Babino, Stefania Barruscotti, Teresa Battista, Mauro Berta, Filippo Biondi, Valeria Boccaletti, Domenico Bonamonte, Francesca Bruni, Rosana Buffon, Stefano Caccavale, Laura Calabrese, Piergiacomo Calzavara Pinton, Elisa Camela, Andrea Carugno, Gabriele Casciola, Elisa Cecchini, Antonio Cristaudo, Michela D'Agostino, Giovanni Damiani, Pietro Danese, Annunziata Dattola, Vincenzo DE Salvo, Enzo Errichetti, Gianluca Esposito, Maria Esposito, Carolina Fantini, Elena Fontana, Luigi Fornaro, Lucretia Adina Frasin, Tommaso Galeotti, Giulia Gasparini, Lucia Genco, Massimo Gravante, Donatella Guastaferro, Gianluca Guerrasio, Luigi Guerriero, Wanda Lauro, Gioacchino Lucagnano, Nicolò Malatesta, Victor Desmond Mandel, Laura Marano, Vincenzo Marino, Fabrizio Martora, Luca Menna, Chiara Miano, Laura Miccio, Andrea Michelerio, Nicola Milanesi, Giuseppe Monfrecola, Alberico Motolese, Mariateresa Nocerino, Matteo Noto, Matteo Ornielli, Alessia Pacifico, Manuela Papini, Giorgio Pasolini, Luca Penchini, Gabriele Perazzolli, Andrea Peserico, Vincenzo Piccolo, Paolo Pigatto, Luca Potestio, Antonio Pugliese, Sebastiano Recalcati, Nicolò Rivetti, Mariateresa Rossi, Filomena Russo, Teresa Russo, Donatella Schena, Chiara Sensini, David Tesauri, Gian Marco Tomassini, Virginia Ventura, Marina Venturini, Pamela Vezzoli, Colombina Vincenzi, Luca, S, Leonardo, B, S, C, Fortina Anna, B, Francesca, C, Monica, C, Alessandro, B, Rosella, G, Ilaria, T, M, F, Andrea, B, Fabrizio, G, Emanuela, M, Maddalena, N, Lucia Mario, D, Cataldo, P, Luigi, B, Paolo, R, Caterina, F, Marta, T, Rossella, M, Giuseppe, A, Katharina, H, Abategiovanni, L, Albertazzi, D, Ali Biglu Marash, S, Amendolagine, G, Angelini, G, Annunziata, A, Assalve, D, Ayala, F, Babino, G, Barruscotti, S, Battista, T, Berta, M, Biondi, F, Boccaletti, V, Bonamonte, D, Bruni, F, Buffon, R, Caccavale, S, Calabrese, L, Calzavara Pinton, P, Camela, E, Carugno, A, Casciola, G, Cecchini, E, Cristaudo, A, D'Agostino, M, Damiani, G, Danese, P, Dattola, A, DE Salvo, V, Errichetti, E, Esposito, G, Esposito, M, Fantini, C, Fontana, E, Fornaro, L, Adina Frasin, L, Galeotti, T, Gasparini, G, Genco, L, Gravante, M, Guastaferro, D, Guerrasio, G, Guerriero, L, Lauro, W, Lucagnano, G, Malatesta, N, Desmond Mandel, V, Marano, L, Marino, V, Martora, F, Menna, L, Miano, C, Miccio, L, Michelerio, A, Milanesi, N, Monfrecola, G, Motolese, A, Nocerino, M, Noto, M, Ornielli, M, Pacifico, A, Papini, M, Pasolini, G, Penchini, L, Perazzolli, G, Peserico, A, Piccolo, V, Pigatto, P, Potestio, L, Pugliese, A, Recalcati, S, Rivetti, N, Rossi, M, Russo, F, Russo, T, Schena, D, Sensini, C, Tesauri, D, Marco Tomassini, G, Ventura, V, Venturini, M, Vezzoli, P, Vincenzi, C, Stingeni Luca, Bianchi Leonardo, Caroppo Elena S, Belloni Fortina Anna, Caroppo Francesca, Corazza Monica, Borghi Alessandro, Gallo Rosella, Trave Ilaria, Ferrucci Silvia M, Beretta Andrea, Guarneri Fabrizio, Martina Emanuela, Napolitano Maddalena, De Lucia Mario, Patruno Cataldo, Bennardo Luigi, Romita Paolo, Foti Caterina, Tramontana Marta, Marietti Rossella, Argenziano Giuseppe, Hansel Katharina, Luisa Abategiovanni, Donatella Albertazzi, Samane Ali Biglu Marash, Graziana Amendolagine, Gianni Angelini, Alberto Annunziata, Danilo Assalve, Fabio Ayala, Graziella Babino, Stefania Barruscotti, Teresa Battista, Mauro Berta, Filippo Biondi, Valeria Boccaletti, Domenico Bonamonte, Francesca Bruni, Rosana Buffon, Stefano Caccavale, Laura Calabrese, Piergiacomo Calzavara Pinton, Elisa Camela, Andrea Carugno, Gabriele Casciola, Elisa Cecchini, Antonio Cristaudo, Michela D'Agostino, Giovanni Damiani, Pietro Danese, Annunziata Dattola, Vincenzo DE Salvo, Enzo Errichetti, Gianluca Esposito, Maria Esposito, Carolina Fantini, Elena Fontana, Luigi Fornaro, Lucretia Adina Frasin, Tommaso Galeotti, Giulia Gasparini, Lucia Genco, Massimo Gravante, Donatella Guastaferro, Gianluca Guerrasio, Luigi Guerriero, Wanda Lauro, Gioacchino Lucagnano, Nicolò Malatesta, Victor Desmond Mandel, Laura Marano, Vincenzo Marino, Fabrizio Martora, Luca Menna, Chiara Miano, Laura Miccio, Andrea Michelerio, Nicola Milanesi, Giuseppe Monfrecola, Alberico Motolese, Mariateresa Nocerino, Matteo Noto, Matteo Ornielli, Alessia Pacifico, Manuela Papini, Giorgio Pasolini, Luca Penchini, Gabriele Perazzolli, Andrea Peserico, Vincenzo Piccolo, Paolo Pigatto, Luca Potestio, Antonio Pugliese, Sebastiano Recalcati, Nicolò Rivetti, Mariateresa Rossi, Filomena Russo, Teresa Russo, Donatella Schena, Chiara Sensini, David Tesauri, Gian Marco Tomassini, Virginia Ventura, Marina Venturini, Pamela Vezzoli, and Colombina Vincenzi

Abstract

Allergic contact dermatitis (ACD) is a common inflammatory skin disease caused by delayed hypersensitivity to chemical and biotic contact allergens. ACD significantly affects the patients' quality of life negatively impacting both occupational and non-occupational settings. Patch testing is the gold standard diagnostic in vivo test to precise the ACD etiology and to correctly perform prevention. According to the Italian Medicines Agency (AIFA) legislative decree no. 178 of 29th May 1991, allergens are defined as medicines and therefore they are subject to strict regulation. In 2017, AIFA (decree no. 2130/2017) started a procedure to regulate contact allergens on the Italian market and actually the contact allergens temporarily authorized are reported in AIFA decree no. 98/2022, valid until November 2023. The availability on the market of contact allergens to diagnose ACD and continuous updating on the basis of new epidemiological trends are mandatory, jointly with the continuous update of the baseline and integrative series for patch testing. For this reason, the scientific community represented in Italy by the Skin Allergies Study Group of SIDeMaST (Italian Society of Dermatology and Venereology) and SIDAPA (Italian Society of Allergological, Occupational and Environmental Dermatology) are constantly working, in close relationship with the European scientific communities with large expertise in this important sector of the modern Dermatology. Herein, we report the setting up of regulatory legislation by AIFA and the new Italian Adult Baseline Series for patch testing.

Published
2024

18. Common Allergens

Author

Foti, Caterina, Bonamonte, Domenico, Romita, Paolo, Guarneri, Fabrizio, Patruno, Cataldo, Angelini, Gianni, Angelini, Gianni, editor, Bonamonte, Domenico, editor, Foti, Caterina, editor, and Pragnell, Mary VC, Translated by

Published
2021
Full Text
View/download PDF

19. Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate‐to‐severe atopic dermatitis: A nationwide retrospective cohort study.

Author

Avallone, Gianluca, Cavallo, Francesco, Tancredi, Annalisa, Maronese, Carlo A., Bertello, Martina, Fraghì, Alessandro, Conforti, Claudio, Calabrese, Giulia, Di Nicola, Matteo R., Oddenino, Giorgio A., Gargiulo, Luigi, Gori, Niccolò, Loi, Camilla, Romita, Paolo, Piras, Viviana, Bonzano, Laura, Tolino, Ersilia, Paolino, Giovanni, Napolitano, Maddalena, and Patruno, Cataldo

Subjects
PREGNANT women, PREGNANCY outcomes, BIOLOGICALS, CHILDBEARING age, BIVARIATE analysis
Abstract

Background: There is limited epidemiological evidence on outcomes associated with dupilumab exposure during pregnancy; monitoring pregnancy outcomes in large populations is required. Objective: To investigate the potential association between exposure to dupilumab in pregnant women with atopic dermatitis and any adverse pregnancy, neonatal, congenital and post‐partum outcomes. Methods: We performed a multicentre retrospective cohort study across 19 Italian tertiary referral hospital. Childbearing women were eligible if aged 18–49 years and carried out the pregnancy between 1 October 2018 and 1 September 2022. Results: We retrospectively screened records of 5062 patients receiving dupilumab regardless of age and gender, identifying 951 female atopic dermatitis patients of childbearing age, 29 of whom had been exposed to the drug during pregnancy (3%). The median duration of dupilumab treatment prior to conception was 22.5 weeks (range: 3–118). The median time of exposure to the drug during pregnancy was 6 weeks (range: 2–24). All the documented pregnancies were unplanned, and the drug was discontinued in all cases once pregnancy status was reported. The comparison of the study cohort and the control group found no significant drug‐associated risk for adverse pregnancy, congenital, neonatal or post‐partum outcomes. The absence of a statistically significant effect of exposure on the event was confirmed by bivariate analysis and multivariate analysis adjusted for other confounding factors. Conclusions: This cohort of pregnant patients exposed to dupilumab adds to the existing evidence concerning the safety of biologic agents in pregnancy. No safety issues were identified regarding the primary outcome assessed. In clinical practice, these data provide reassurance in case of dupilumab exposure during the first trimester. However, the continuous use of dupilumab throughout pregnancy warrants further research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis

Author

Pezzolo, Elena, primary, Ortoncelli, Michela, additional, Ferrucci, Silvia Mariel, additional, Guanti, Mario Bruno, additional, Schena, Donatella, additional, Napolitano, Maddalena, additional, Rossi, Mariateresa, additional, Foti, Caterina, additional, D’Amico, Domenico, additional, Amoruso, Giuseppe Fabrizio, additional, Morrone, Pietro, additional, Ribero, Simone, additional, Barei, Francesca, additional, Biagi, Matteo, additional, Pascucci, Enrico, additional, Patruno, Cataldo, additional, Calzavara Pinton, Piergiacomo, additional, Romita, Paolo, additional, Gargiulo, Luigi, additional, Narcisi, Alessandra, additional, and Naldi, Luigi, additional

Published
2024
Full Text
View/download PDF

26. Injection site reactions after dupilumab or tralokinumab for atopic dermatitis.

Author

Martor, Fabrizio, Patruno, Cataldo, D’Ascenzo, Silvia, and Napolitano, Maddalena

Subjects
*ATOPIC dermatitis, *DUPILUMAB, *SUBCUTANEOUS injections, *INJECTIONS, *ITCHING
Abstract

Background: Injection site reaction (ISR) is a local phenomenon defined as a constellation of symptoms, including swelling, erythema, pruritus, and pain around the site of injection. Objective: ISR is reported as a frequent adverse event after subcutaneous injection (SCI) of several biologics. Methods: We performed an observational real-life study to compare dupilumab and tralokinumab as regards ISR, analysing frequency, duration and intensity of symptoms related to SCI. From January 2023 to June 2023, we enrolled adult patients affected by moderate to severe AD and being on dupilumab or tralokinumab treatment. A 12 items questionnaire was administered to all enrolled patients. Results and conclusions: Three hundred and ninety-two patients were included. ISR was a frequent occurrence in both the treatment groups, with tralokinumab causing ISR more frequently than dupilumab. However, the reactions were generally mild and no patient stopped therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Contact allergy to SIDAPA baseline series allergens in patients with eyelid dermatitis: An Italian multicentre study.

Author

Stingeni, Luca, Foti, Caterina, Guarneri, Fabrizio, Corazza, Monica, Cristaudo, Antonio, Ferrucci, Silvia Mariel, Gallo, Rosella, Martina, Emanuela, Musumeci, Maria Letizia, Napolitano, Maddalena, Nettis, Eustachio, Patruno, Cataldo, Pigatto, Paolo Daniele, Piras, Viviana, Schena, Donatella, Casciola, Gabriele, Antonelli, Elettra, Hansel, Katharina, Bianchi, Leonardo, and Borghi, Alessandro

Abstract

Background: Eyelid dermatitis is a frequent reason of dermatological consultation. Its aetiology is not univocal, being contact dermatitis, both allergic and irritant, the most frequent. The primary sources of allergen exposure include cosmetics, metals, and topical medications, from direct, indirect, or airborne contact. Objectives: To define the frequency of positive patch test reactions to SIDAPA baseline series allergens, to document positive allergens, and to precise the final diagnosis in patients with eyelid involvement. Methods: A total of 8557 consecutive patients from 12 Italian Dermatology Clinics underwent patch testing with SIDAPA baseline series in 2018 and 2019. Patients were divided into two groups: (i) with eyelid involvement with or without other involved sites (E‐Group) and (ii) without eyelid involvement (NE‐Group). The final diagnosis and the frequency of positive relevant patch test reactions were evaluated. Results: E‐Group consisted of 688 patients (females 78.6%, mean age 45.3 years), 8.0% of 8557 consecutively patch‐tested patients. The final diagnosis in E‐Group was ADC in 42.4%, ICD in 34.2%, and AD in 30.5%. The highest reaction rates were elicited by nickel sulphate and methylchloroisothiazolinone/methylisothiazolinone in both E‐Group and NE‐Group, even if these allergens were significantly more frequently positive in NE‐Group patients than in E‐Group ones. Positive patch test reactions to fragrance Mix II, dimethylaminopropylamine, and sorbitan sesquiolate were significantly more frequent in E‐Group patients than in NE‐Group ones. Conclusions: Eyelid dermatitis is a frequent dermatological complaint. Allergic contact dermatitis is the most frequent diagnosis commonly caused by nickel sulphate, isothiazolinones, and fragrances. The surfactants dimethylaminopropylamine and sorbitan sesquioleate are emerging causes of eyelid allergic contact dermatitis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Safety of omalizumab in chronic urticaria during pregnancy: a real-life study.

Author

Patruno, Cataldo, Guarneri, Fabrizio, Nettis, Eustachio, Bonzano, Laura, Filippi, Federica, Ribero, Simone, Foti, Caterina, Rubegni, Pietro, Balato, Anna, Miniello, Andrea, Motolese, Alfonso, Piraccini, Bianca Maria, Quaglino, Pietro, Romita, Paolo, Lazzeri, Laura, Buononato, Dario, Dastoli, Stefano, Raia, Flavia, and Napolitano, Maddalena

Subjects
*PREGNANT women, *OMALIZUMAB, *PREGNANCY complications, *URTICARIA, *PREGNANCY, *PATIENT safety
Abstract

Background Managing a pregnant patient with chronic spontaneous urticaria (CSU) is often challenging. Recent data have shown that most CSU treatments in pregnant patients are second-generation H1 antihistamines (sgAHs), while data on the safety of omalizumab are scant. Objectives To evaluate, in a routine clinical practice setting, the efficacy and safety of omalizumab in patients with severe CSU refractory to sgAHs who either became pregnant during treatment or who started the drug during pregnancy. Methods We conducted a retrospective study of women aged ≥ 18 years who were pregnant, who received one or more doses of omalizumab at any time during their pregnancy or who were taking omalizumab at the time of, or in the 8 weeks before, conception. Results Twenty-nine pregnant patients were evaluated: 23 (79%) conceived a child while taking omalizumab (group A), while 6 (21%) started omalizumab treatment during pregnancy (group B). Among patients in group A, we observed 23 births (21 liveborn singletons and 1 liveborn twin pair) and 1 miscarriage. Fifteen (65%) patients discontinued omalizumab after confirming their pregnancy, while eight (35%) were exposed to omalizumab during their entire pregnancy. In group B, omalizumab was introduced at a mean (SD) 10.83 (3.60) weeks' gestation and all patients were exposed to it until the end of pregnancy. In this group, there were seven liveborn infants (five singletons and one twin pair). No adverse events, pregnancy complications or congenital anomalies in newborns were recorded in either group. Conclusions Omalizumab for CSU treatment before and during pregnancy does not appear to have negative effects on maternal or fetal outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Dupilumab-associated inflammatory arthritis: a literature review.

Author

Napolitano, Maddalena, Ruggiero, Angelo, and Patruno, Cataldo

Subjects
LITERATURE reviews, ARTHRITIS, ATOPIC dermatitis, CELLULAR signal transduction, THERAPEUTICS
Abstract

Dupilumab is a fully human monoclonal antibody that acts by inhibiting the interleukin (IL)-4 receptor subunit α, and hence the IL-4 and IL-13 signalling pathway. Dupilumab treatment has been linked to the onset of T helper 17-driven inflammatory diseases, including cases of seronegative arthritis and enthesitis. To date, dupilumab-associated inflammatory arthritis (DAIA) represents a relatively unknown adverse event, initially reported in single cases or case series reports. Indeed, the onset of DAIA may not be promptly recognized, and is probably underestimated. Here we have reviewed the available English literature regarding arthritis and enthesitis onset during dupilumab treatment for atopic dermatitis, aiming to improve rapid recognition and thus prompt treatment of these diseases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

32. Patients Withdrawing Dupilumab Monotherapy for COVID-19–Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author

Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iris, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, and Peris, Ketty

Published
2021
Full Text
View/download PDF

33. Patients Withdrawing Dupilumab Monotherapy for COVID-19–Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author

Chiricozzi, Andrea, Di Nardo, Lucia, Talamonti, Marina, Galluzzo, Marco, De Simone, Clara, Fabbrocini, Gabriella, Marzano, Angelo Valerio, Girolomoni, Giampiero, Offidani, Annamaria, Rossi, Maria Teresa, Bianchi, Luca, Cristaudo, Antonio, Fierro, Maria Teresa, Stingeni, Luca, Pellacani, Giovanni, Argenziano, Giuseppe, Patrizi, Annalisa, Pigatto, Paolo, Romanelli, Marco, Savoia, Paola, Rubegni, Pietro, Foti, Caterina, Milanesi, Nicola, Belloni Fortina, Anna, Bongiorno, Maria Rita, Grieco, Teresa, Di Nuzzo, Sergio, Fargnoli, Maria Concetta, Carugno, Andrea, Motolese, Alberico, Rongioletti, Franco, Amerio, Paolo, Balestri, Riccardo, Potenza, Concetta, Micali, Giuseppe, Patruno, Cataldo, Zalaudek, Iris, Lombardo, Maurizio, Feliciani, Claudio, Antonelli, Flaminia, Ferrucci, Silvia Mariel, Guarneri, Fabrizio, and Peris, Ketty

Published
2022
Full Text
View/download PDF

38. Safety of omalizumab for chronic urticaria during pregnancy: a real-life study

Author

Patruno, Cataldo, primary, Guarneri, Fabrizio, additional, Nettis, Eustachio, additional, Bonzano, Laura, additional, Filippi, Federica, additional, Ribero, Simone, additional, Foti, Caterina, additional, Rubegni, Pietro, additional, Balato, Anna, additional, Miniello, Andrea, additional, Motolese, Alfonso, additional, Piraccini, Bianca Maria, additional, Quaglino, Pietro, additional, Romita, Paolo, additional, Lazzeri, Laura, additional, Buonanto, Dario, additional, Dastoli, Stefano, additional, Raia, Flavia, additional, and Napolitano, Maddalena, additional

Published
2023
Full Text
View/download PDF

42. Head–neck melanoma: Clinical, histopathological and prognostic features of an Italian multicentric study

Author

Schipani, Giusy, primary, Nisticò, Steven P., additional, Quaglino, Pietro, additional, Ribero, Simone, additional, Gallo, Giuseppe, additional, Maione, Vincenzo, additional, Girolomoni, Giampiero, additional, Rosina, Paolo, additional, Alaibac, Mauro, additional, Messina, Francesco, additional, Gatti, Alessandro, additional, Stinco, Giuseppe, additional, Buligan, Cinzia, additional, Bassoli, Sara, additional, Farnetani, Francesca, additional, Borghi, Alessandro, additional, Melandri, Davide, additional, Sirna, Riccardo, additional, Feci, Luca, additional, Simonetti, Stefano, additional, Stingeni, Luca, additional, Offidani, Annamaria, additional, Brisigotti, Valerio, additional, Campanati, Anna, additional, Calvieri, Stefano, additional, Spallone, Giulia, additional, Botti, Elisabetta, additional, Panasiti, Vincenzo, additional, Pagnanelli, Gianluca, additional, Scalvenzi, Massimiliano, additional, Fabbrocini, Gabriella, additional, Costa, Claudia, additional, Schirripa, Vincenzo, additional, Borgia, Francesco, additional, Atzori, Laura, additional, Scali, Elisabetta, additional, Passante, Maria, additional, Guarneri, Fabrizio, additional, and Patruno, Cataldo, additional

Published
2023
Full Text
View/download PDF

44. Quality of life in patients with allergic and immunologic skin diseases: in the eye of the beholder

Author

Di Agosta, Ester, Salvati, Lorenzo, Corazza, Monica, Baiardini, Ilaria, Ambrogio, Francesca, Angileri, Luisa, Antonelli, Elettra, Belluzzo, Federica, Bonamonte, Domenico, Bonzano, Laura, Brancaccio, Raffaele, Custurone, Paolo, De Marco, Aurora, Detoraki, Aikaterini, Di Guida, Adriana, Di Leo, Elisabetta, Fantò, Marta, Fassio, Filippo, Ferrucci, Silvia Mariel, Foti, Caterina, Gallo, Rosella, Gatta, Alessia, Guarneri, Fabrizio, Guidolin, Lucia, Hansel, Katharina, Lamacchia, Donatella, Lombardo, Carla, Minciullo, Paola Lucia, Napolitano, Maddalena, Pannofino, Alessandro, Paravisi, Andrea, Parente, Roberta, Passante, Maria, Patruno, Cataldo, Peroni, Diego, Quecchia, Cristina, Schettini, Natale, Spadaro, Giuseppe, Stingeni, Luca, Tarrini, Daniele, Tramontana, Marta, Nettis, Eustachio, and Rossi, Oliviero

Published
2021
Full Text
View/download PDF

46. Frequency of contact allergy to pentylene glycol. Retrospective cross‐sectional study with data from the Società Italiana di Dermatologia Allergologica Professionale e Ambientale (SIDAPA).

Author

Gallo, Rosella, Guarneri, Fabrizio, Ferrucci, Silvia Mariel, Stingeni, Luca, Hansel, Katharina, Corazza, Monica, Borghi, Alessandro, Foti, Caterina, Romita, Paolo, Patruno, Cataldo, Napolitano, Maddalena, Morini, Nicole, Trave, Ilaria, Rigano, Luigi, and Parodi, Aurora

Published
2024
Full Text
View/download PDF

47. Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response Factors.

Author

Potestio, Luca, Patruno, Cataldo, and Napolitano, Maddalena

Abstract

Background: Tralokinumab has been recently approved for the management of moderate-to-severe atopic dermatitis (AD). Despite its effectiveness and safety have been widely reported, there are no studies investigating factors that may affect clinical outcomes. Objective: To evaluate the effectiveness and safety of tralokinumab, also to investigate possible predictive response factors that may affect the time of onset of treatment response. Methods: A monocentric retrospective real-life study was performed enrolling AD patients undergoing treatment with tralokinumab for at least 24 weeks. AD severity was assessed at baseline and at week (W)16, and W24. Similarly, treatment-related adverse events (AEs) were evaluated at each follow-up visit. Results: A total of 57 patients were enrolled. AD severity started to improve at W4, continued to improve at W16 and W24. In our cohort, we found out that gender, age, atopic comorbidities, and previous treatments did not affect treatment outcomes. However, we observed that patients with higher Pruritus-Numerical Rating Scale (‡8), relapsing form of AD, Eczema Area and Severity Index (EASI) £24, and Investigator Global Assessment (IGA) £3 achieved more frequently EASI75 response at W16. No significant AEs were collected. Conclusions: Our study confirmed the effectiveness and safety of tralokinumab. In particular, a higher pruritus, a relapsing course of the disease, a reduced EASI, a reduced IGA, and a brief duration of the disease seem to be associated with the fastest onset of treatment effectiveness. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. AtopyReg®, the Prospective Italian Patient Registry for Moderate-to-Severe Atopic Dermatitis in Adults: Baseline Demographics, Disease Characteristics, Comorbidities, and Treatment History.

Author

Stingeni, Luca, Chiricozzi, Andrea, Calzavara-Pinton, Piergiacomo, Napolitano, Maddalena, Peris, Ketty, Schena, Donatella, Patruno, Cataldo, Rossi, Mariateresa, Foti, Caterina, Fargnoli, Maria C., Corazza, Monica, Ferrucci, Silvia M., Pigatto, Paolo D., Romanelli, Marco, Fabbrocini, Gabriella, Girolomoni, Giampiero, Passante, Maria, Romita, Paolo, Esposito, Maria, and Schettini, Natale

Subjects
ATOPIC dermatitis, RESEARCH funding, QUALITY of life, DEMOGRAPHY, COMORBIDITY, ADULTS
Abstract

Background and Objective: AtopyReg® is a multicenter, prospective, observational, non-profit cohort study on moderate-to-severe atopic dermatitis in adults promoted in 2018 by the Italian Society of Dermatology and Venereology (SIDeMaST). We aimed to describe baseline demographics, disease characteristics, comorbidities, and therapeutic data of adult patients affected by moderate-to-severe atopic dermatitis. Methods: Patients were selected based on the following inclusion criteria: age ≥ 18 years; Eczema Area and Severity Index score ≥ 16 or localization in visible or sensitive areas (face, neck, hands, or genitalia), or a Numeric Rating Scale itch score ≥ 7 or a Numeric Rating Scale sleep loss score ≥ 7, or a Dermatology Life Quality Index score ≥ 10. Demographic and clinical data at baseline were recorded and analyzed. Results: A total of 1170 patients (male 51.1%; mean age: 44.7 years; range 18–90 years) were enrolled by 12 Italian Dermatology Units between January 2019 and November 2022. Skin lesions were eczematous in 83.2% of patients, the most involved site were the flexures (53.9%), face (50.9%), and neck (48.0%). Mean Eczema Area and Severity Index score was 22.3, mean Dermatology Life Quality Index value was 17.6, mean Patient Oriented Eczema Measure score was 13.1, and mean Numeric Rating Scale itch and sleep loss scores were 7.6 and 5.9, respectively. Previous systemic therapies were corticosteroids in 77.7% of patients, antihistamines in 50.3% of patients, and cyclosporine A in 42.6% of patients. Conclusions: This baseline data analysis deriving from AtopyReg® provides real-life evidence on patients with moderate-to-severe atopic dermatitis in Italy confirming the high burden of atopic dermatitis with a significant impact on patients' quality of life. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years

Author

Patruno, Cataldo, primary, Fabbrocini, Gabriella, additional, Lauletta, Giuseppe, additional, Boccaletti, Valeria, additional, Colonna, Cristiana, additional, Cavalli, Riccardo, additional, Neri, Iria, additional, Ortoncelli, Michela, additional, Schena, Donatella, additional, Stingeni, Luca, additional, Hansel, Katharina, additional, Piccolo, Vincenzo, additional, Di Brizzi, Veronica, additional, Potenza, Concetta, additional, Tolino, Ersilia, additional, Bianchi, Luca, additional, Manti, Sara, additional, De Pasquale, Rocco, additional, Di Lernia, Vito, additional, Caminiti, Lucia, additional, Galli, Elena, additional, Coppo, Paola, additional, Chiricozzi, Andrea, additional, De Simone, Clara, additional, Guerriero, Cristina, additional, Amoruso, Fabrizio Giuseppe, additional, Provenzano, Eugenio, additional, Leonardi, Salvatore, additional, Licari, Amelia, additional, Marseglia, Gian Luigi, additional, Palermo, Antonino, additional, Di Pillo, Sabrina, additional, Russo, Daniele, additional, Moschese, Viviana, additional, Patella, Vincenzo, additional, Peduto, Tiziana, additional, Ferreli, Caterina, additional, Zangari, Paola, additional, Veronese, Federica, additional, Berti, Samantha Federica, additional, Gruber, Michaela, additional, Pezzolo, Elena, additional, Termine, Stefania, additional, Satta, Rosanna, additional, Dragoni, Federica, additional, Esposito, Maria, additional, Fargnoli, Maria Concetta, additional, Chiodini, Paolo, additional, Vallone, Ylenia, additional, di Vico, Francesca, additional, Picone, Vincenzo, additional, and Napolitano, Maddalena, additional

Published
2023
Full Text
View/download PDF

50. Airborne allergic contact dermatitis 'by proxy' due to budesonide

Author

Napolitano, Maddalena, Martora, Fabrizio, Martora, Lorenzo, Picone, Vincenzo, Passante, Maria, Fabbrocini, Gabriella, Patruno, Cataldo, Napolitano, Maddalena, Martora, Fabrizio, Martora, Lorenzo, Picone, Vincenzo, Passante, Maria, Fabbrocini, Gabriella, and Patruno, Cataldo

Subjects
Infectious Diseases, Dermatology
Published
2023

Catalog

Books, media, physical & digital resources
See catalog results